Pharvaris (PHVS)

• Market cap: $1.06B
• 1 day: 3.56%
• 5 days: 3.83%
• 1 month: -19.32%
• 3 months: 3.23%
• 6 months: 6.79%
• Year to date: -24.62%
• 1 year: -25.71%
• 5 years: -32.76%
• 10 years: -32.76%

About: Pharvaris NV is a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.

Employees: 82

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

375% more first-time investments, than exits

New positions opened: 19 | Existing positions closed: 4

71% more repeat investments, than reductions

Existing positions increased: 12 | Existing positions reduced: 7

42% more funds holding

Funds holding: 36 [Q2] → 51 (+15) [Q3]

3.45% more ownership

Funds ownership: 79.96% [Q2] → 83.4% (+3.45%) [Q3]

3% more capital invested

Capital invested by funds: $809M [Q2] → $834M (+$25.2M) [Q3]

0% more funds holding in top 10

Funds holding in top 10: 6 [Q2] → 6 (+0) [Q3]